Digene Rapid Capture
This article was originally published in The Gray Sheet
Executive Summary
PMA supplement for high-volume sample throughput instrument is submitted to FDA for use with the firm's DNAwithPap HPV test. The system incorporates automated pipetting and microplate processing to analyze over 350 patient samples in an eight-hour lab shift, Digene claims...
You may also be interested in...
Digene Rapid Capture
High-volume sample throughput instrument gains PMA supplement approval for use with the firm's HC2 HPV DNA test, also marketed as DNAwithPap for primary human papillomavirus screening in conjunction with Pap smear. The system incorporates automated pipetting and microplate processing to analyze 352 patient samples in a 6.5-hour lab shift, and is expected to facilitate DNAwithPap adoption by large labs, Digene says (1"The Gray Sheet" Nov. 10, 2003, In Brief). Rapid Capture previously was cleared for use with Digene chlamydia and gonorrhea tests. HPV sales drove Digene revenue up 39% to $23.6 mil. for its fiscal third quarter (ended March 31)...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.